At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 184 enrolled
Drug / intervention
Depot medroxyprogesterone acetate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding Continuation, Contraceptive Continuation, and Postpartum Depression: a Randomized Trial
In Brief
A Phase 4 clinical trial evaluating Depot medroxyprogesterone acetate for Contraception and 2 related conditions. Completed, enrolled 184 participants across 1 site.
Detailed Summary
The investigators plan to enroll 184 women who are planning to breastfeed and use DMPA after delivery to find out whether the timing of postpartum administration of DMPA (prior to hospital discharge or 4-6 weeks after delivery) affects the duration or exclusivity of breastfeeding among women who plan to breastfeed their infants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception, Postpartum Depression, Lactation
CountriesUnited States
CollaboratorsSociety of Family Planning
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartNov 2011
Primary CompletionFeb 2017
Study CompletionOct 2017
TodayJul 2026
First PostedNov 1, 2011
Enrollment StartNov 1, 2011
Primary CompletionFeb 13, 2017
Study CompletionOct 16, 2017
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 14.7 years ago
Interventions
Depot medroxyprogesterone acetatedrug
Postpartum administration of DMPA (prior to hospital discharge)
Depot medroxyprogesterone acetatedrug
Delayed administration of DMPA (4-6 weeks postpartum)